In-Silico Identification of Immunogenic Peptide Epitopes for the Design of a Multi-Epitope Therapeutic Vaccine against Triple-Negative Breast Cancer
Archives of Advances in Biosciences,
Vol. 16 No. 1 (2025),
2 March 2025
,
Page 1-10
https://doi.org/10.22037/aab.v16i1.48314
Abstract
Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 expression, which limits the efficacy of conventional targeted therapies. Immunotherapy, particularly peptide-based therapeutic vaccines, offers a promising alternative strategy by harnessing the body’s cytotoxic T lymphocyte (CTL) responses against tumor-specific antigens (TSAs). This study aimed to identify and validate immunogenic peptide epitopes derived from highly tumor-specific antigens for the design of a multi-epitope vaccine targeting TNBC.
Materials and Method: Using a comprehensive immunoinformatics workflow, tumor-associated antigens with high immunogenic potential—Survivin (BIRC5), MAGE-A3, and NY-ESO-1—were selected based on expression profiles and previous evidence of immunoreactivity. Candidate epitopes were predicted through NetCTL, SYFPEITHI, and MHCflurry servers, with selection criteria including strong binding affinity to HLA-A*02:01, favorable proteasomal cleavage patterns, TAP transport efficiency, and minimal cross-reactivity.
Results: Three high-scoring CD8⁺ T-cell epitopes were identified—LMLGEFLKL from Survivin (BIRC5), FLWGPRALA from MAGE-A3, and SLLMWITQC from NY-ESO-1. All epitopes exhibited IC50 values below 50 nM and high immunogenicity scores, supporting their suitability for incorporation into a multi-epitope vaccine construct targeting TNBC.
Conclusion: Our results support the rational design of a peptide-based therapeutic vaccine for TNBC by integrating three validated epitopes derived from the tumor antigens Survivin, MAGE-A3, and NY-ESO-1. This study contributes to the growing field of cancer immunotherapy by offering a novel, computationally driven approach for vaccine development against refractory breast cancers.
- peptide vaccine
- immunoinformatics
- epitope prediction
- CTL response
- Triple negative breast cancer
- tumor specific antigen
How to Cite
References
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature reviews Clinical oncology. 2016 Nov;13(11):674-90.[PMID]
Rokhzadi K, Haji-Allahverdipoor K. Advancements in Emerging Molecular Approaches: Promising Diagnostic and Therapies Methods for Triple-Negative Breast Cancer (TNBC) Treatment. International Journal of BioLife Sciences (IJBLS). 2023 Oct 2;2(2):221-9.[LINK]
Choupani E, Gomari MM, Zanganeh S, Nasseri S, Haji-Allahverdipoor K, Rostami N, Hernandez Y, Najafi S, Saraygord-Afshari N, Hosseini A. Newly developed targeted therapies against the androgen receptor in triple-negative breast cancer: a review. Pharmacological reviews. 2023 Mar 1;75(2):309-27.[PMID]
Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of clinical oncology. 2008 Mar 10;26(8):1275-81.[PMCID]
Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018 Mar 23;359(6382):1355-60.[PMCID]
Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clinical cancer research. 2009 Sep 1;15(17):5323-37.[PMCID]
Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC bioinformatics. 2007 Oct 31;8(1):424.[PMCID]
Rammensee HG, Bachmann J, Emmerich NP, Bachor OA, Stevanović SS. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999 Nov;50(3):213-9.[PMCID]
O’Donnell TJ, Rubinsteyn A, Laserson U. MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing. Cell systems. 2020 Jul 22;11(1):42-8.[PMCID]
Leclerc M, Kresdorn N, Rotter B. Evidence of complement genes in the sea-star Asterias rubens. Comparisons with the sea urchin. Immunology Letters. 2013 Mar 1;151(1-2):68-70.[LINK]
Kanwar JR, Kamalapuram SK, Kanwar RK. Survivin signaling in clinical oncology: a multifaceted dragon. Medicinal research reviews. 2013 Jul;33(4):765-89. [PMCID]
Paul S, Weiskopf D, Angelo MA, Sidney J, Peters B, Sette A. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. The Journal of Immunology. 2013 Dec;191(12):5831-9. [PMCID]
Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I–restricted T lymphocyte responses. Annual review of immunology. 1999 Apr;17(1):51-88.[PMCID]
Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998 Dec 10;396(6711):580-4.[PMID]
Bernatchez C, Zhu K, Li Y, Andersson H, Ionnides C, Fernandez-Vina M, Cano P, Cooper L, Abbruzzese J, Hwu P, Chang DZ. Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. Vaccine. 2011 Apr 5;29(16):3021-30. [PMID]
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011 Dec 22;480(7378):480-9. [PMCID]
Sette A, Peters B. Immune epitope mapping in the post-genomic era: lessons for vaccine development. Current Opinion in Immunology. 2007 Feb 1;19(1):106-10. [PMCID]
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews cancer. 2012 Apr;12(4):252-64.[PMCID]
- Abstract Viewed: 146 times
- PDF Downloaded: 71 times